Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


Late gastrointestinal toxicities following radiation therapy for prostate cancer.

Kim S, Shen S, Moore DF, Shih W, Lin Y, Li H, Dolan M, Shao YH, Lu-Yao GL.

Eur Urol. 2011 Nov;60(5):908-16. doi: 10.1016/j.eururo.2011.05.052. Epub 2011 Jun 12.


Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.

Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ.

Eur Urol. 2011 Dec;60(6):1142-8. doi: 10.1016/j.eururo.2011.08.006. Epub 2011 Aug 12.


A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.

Fang P, Mick R, Deville C, Both S, Bekelman JE, Christodouleas JP, Guzzo TJ, Tochner Z, Hahn SM, Vapiwala N.

Cancer. 2015 Apr 1;121(7):1118-27. doi: 10.1002/cncr.29148. Epub 2014 Nov 25.


Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.

Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stürmer T, Holmes JA, Reeve BB, Godley PA, Carpenter WR, Chen RC.

JAMA. 2012 Apr 18;307(15):1611-20. doi: 10.1001/jama.2012.460.


Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.

Morimoto M, Yoshioka Y, Konishi K, Isohashi F, Takahashi Y, Ogata T, Koizumi M, Teshima T, Bijl HP, van der Schaaf A, Langendijk JA, Ogawa K.

Tumori. 2014 May-Jun;100(3):265-71. doi: 10.1700/1578.17198.


Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL.

Eur Urol. 2015 Nov;68(5):805-11. doi: 10.1016/j.eururo.2015.03.021. Epub 2015 Mar 21.


Late GI and bladder toxicities after radiation for uterine cancer.

Samper-Ternent R, Zhang D, Kuo YF, Hatch S, Freeman J.

Gynecol Oncol. 2011 Feb;120(2):198-204. doi: 10.1016/j.ygyno.2010.10.017. Epub 2010 Nov 16.


Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last?

Kim S, Moore DF, Shih W, Lin Y, Li H, Shao YH, Shen S, Lu-Yao GL.

J Urol. 2013 Jan;189(1):116-21. doi: 10.1016/j.juro.2012.08.091. Epub 2012 Nov 16.


Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.

Shu HK, Lee TT, Vigneauly E, Xia P, Pickett B, Phillips TL, Roach M.

Urology. 2001 Jan;57(1):102-7.


Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both.

Jarosek SL, Virnig BA, Chu H, Elliott SP.

Eur Urol. 2015 Feb;67(2):273-80. doi: 10.1016/j.eururo.2014.08.061. Epub 2014 Sep 10.


Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.

Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1124-9. doi: 10.1016/j.ijrobp.2007.11.044.


Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy.

Liu M, Pickles T, Agranovich A, Berthelet E, Duncan G, Keyes M, Kwan W, McKenzie M, Morris J, Pai H, Tyldesley S, Wu J.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):59-67.


Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.

Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, Lewinger JP, Stern MC, Hamilton AS, Aron M, Gill IS.

J Urol. 2015 Aug;194(2):378-85. doi: 10.1016/j.juro.2015.02.084. Epub 2015 Feb 21.


Comparison and limitations of DVH-based NTCP models derived from 3D-CRT and IMRT data for prediction of gastrointestinal toxicities in prostate cancer patients by using propensity score matched pair analysis.

Troeller A, Yan D, Marina O, Schulze D, Alber M, Parodi K, Belka C, Söhn M.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):435-43. doi: 10.1016/j.ijrobp.2014.09.046.


The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397).

Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP.

Clin Oncol (R Coll Radiol). 2011 Nov;23(9):613-24. doi: 10.1016/j.clon.2011.03.001. Epub 2011 Apr 5.


Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.

Sutani S, Ohashi T, Sakayori M, Kaneda T, Yamashita S, Momma T, Hanada T, Shiraishi Y, Fukada J, Oya M, Shigematsu N.

Radiother Oncol. 2015 Nov;117(2):270-6. doi: 10.1016/j.radonc.2015.08.019. Epub 2015 Aug 26.


Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L.

Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Erratum in: Lancet Oncol. 2015 Mar;16(3):e105.


Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.

Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler HM.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8. doi: 10.1016/j.ijrobp.2013.07.041. Epub 2013 Oct 8.


Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy.

Tanaka N, Asakawa I, Anai S, Hirayama A, Hasegawa M, Konishi N, Fujimoto K.

Radiat Oncol. 2013 Jan 30;8:25. doi: 10.1186/1748-717X-8-25.

Supplemental Content

Support Center